Bufrolin is a potent GPR35 agonist and a cromoglycate analog that promotes the interaction between β-arrestin-2 and human GPR35a or rat GPR35; it acts as a mast cell stabilizer with anti-allergic properties and inhibits internalization peptide-induced anti-inflammatory responses; it can be used as an anti-inflammatory agent in drug delivery studies involving internalization peptide-conjugated agents.